Compare ING Groep NV (ING) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Novavax Inc — how do they compare? ING Groep NV trades at $33.26 (market cap $93.76B), while Novavax Inc trades at $12.58 (market cap $1.82B). The key difference: ING Groep NV is far larger — about 51.5× Novavax Inc's market cap, and ING Groep NV pays a 3.95% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and Novavax Inc for 59 Days on average.
| ING | NVAX | |
|---|---|---|
Market Cap | $93.76B | $1.82B |
Volume | 4,620,220 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $37.27 | $12.56 |
52-Week Low | $23.66 | $6.22 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $236.48B | $1.39B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.28, down 1.89% today, with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains a 28.34% net income margin, and analysts show strong support with 11 buy ratings versus no sell ratings. Recent news highlights management's raised ROE target above 16% for 2027 and strategic focus on organic growth.
The investment case balances solid profitability and analyst optimism against technical weakness and cash flow challenges. Upside potential exists from earnings momentum and strategic initiatives, while risks include persistent negative operating cash flows and regulatory scrutiny in international markets.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
